Compugen (CGEN) Income from Continuing Operations (2009 - 2026)
Compugen's (CGEN) quarterly Income from Continuing Operations came in at 7659000.0 in Q1 2026, up 7.59% year-on-year from 7119000.0 in Q1 2025, and down 86.5% quarter-over-quarter from 56737000.0 in Q4 2025.
Compugen (CGEN) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Compugen has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 7659000.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 7659000.0, up 7.59% year-over-year; the trailing twelve-month figure through Mar 2026 was 35883000.0 (up 772.34% YoY), and the FY2025 annual result was 35343000.0, up 348.35% from the prior year.
- Income from Continuing Operations came in at 7659000.0 for Q1 2026 at Compugen, down from 56737000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 56737000.0 in Q4 2025 to a low of 28000000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 3092000.0 (2022), against an average of 1352647.06.
- Across the five-year window, Income from Continuing Operations tumbled 198.03% in 2023 and jumped 1027.53% in 2025, its largest moves.
- Compugen's Income from Continuing Operations stood at 3092000.0 in 2022, then surged by 414.13% to 9713000.0 in 2023, then plunged by 162.98% to 6117000.0 in 2024, then surged by 1027.53% to 56737000.0 in 2025, then tumbled by 86.5% to 7659000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 7659000.0 (Q1 2026), 56737000.0 (Q4 2025), and 6899000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Compugen | 189.59 Mn | 97.83 Mn | 352,000.00 | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 56.74 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -21.61 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | -6.12 Mn |
| Sep 30, 2024 | 10.28 Mn |
| Jun 30, 2024 | -16.62 Mn |
| Mar 31, 2024 | 7.26 Mn |
| Dec 31, 2023 | 9.71 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -28.00 Mn |
| Mar 31, 2023 | 9.31 Mn |
| Dec 31, 2022 | -3.09 Mn |
| Sep 30, 2022 | -11.75 Mn |
| Jun 30, 2022 | 28.56 Mn |
| Mar 31, 2022 | -9.71 Mn |
| Dec 31, 2021 | -8.65 Mn |
| Sep 30, 2021 | -8.18 Mn |
| Jun 30, 2021 | -9.50 Mn |